 <h1>Zoster vaccine live Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to zoster vaccine live: subcutaneous powder for suspension</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, zoster vaccine live may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking zoster vaccine live:</p><p>
<i>Less common</i>
</p><ul>
<li>Collection of blood under the skin, a deep, dark purple bruise, itching, pain, redness, swelling, or a hard lump at the injection site</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blurred vision</li>
<li>change in color vision</li>
<li>cough</li>
<li>difficulty seeing at night</li>
<li>difficulty swallowing</li>
<li>dizziness</li>
<li>eye redness</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>hives, itching, skin rash</li>
<li>increased sensitivity of the eyes to sunlight</li>
<li>pain around the eyes</li>
<li>painful blisters on the trunk of the body</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>temporary swollen, painful, or tender lymph glands in the neck, armpit, or groin</li>
<li>tightness in the chest</li>
<li>unusual tiredness or weakness</li>
<li>vision loss</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of zoster vaccine live may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Headache</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Difficulty in moving</li>
<li>joint pain or swelling</li>
<li>muscle ache, cramp, pain, or stiffness</li>
<li>nausea</li>
</ul><p>
<!-- end subcutaneous powder for suspension --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to zoster vaccine live: subcutaneous powder for injection</i></p><h3>General</h3><p>The most common adverse events were headache and injection site reactions.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site pain (up to 53.9%), injection site erythema (48.1%), injection site swelling (40.4%), pruritus (11.3%)</p>
<p><b>Common</b> (1% to 10%): Warmth, hematoma, induration</p>
<p><b>Postmarketing reports</b>: Injection site rash, injection site urticaria, transient injection site lymphadenopathy<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, asthenia<sup>[Ref]</sup></p><h3>Other</h3><p>The most common reported cause of death was cardiovascular disease (10 in the vaccine group, 8 in the placebo group).  The overall incidence of death occurring at any time during the study was similar between groups: 793 deaths (4.1%) in the vaccine group and 795 deaths (4.1%) in the placebo group.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Death, fever, asthenia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Congestive heart failure or pulmonary edema<sup>[Ref]</sup></p><p>Congestive heart failure or pulmonary edema occurred in 1.5% of patients receiving the vaccine versus 1.2% of patients receiving placebo in the AE monitoring substudy.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Respiratory infection, flu syndrome, rhinitis, respiratory disorder</p>
<p><b>Very rare</b> (less than 0.01%): Asthma exacerbation<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea</p>
<p><b>Postmarketing reports</b>: Nausea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Skin disorder</p>
<p><b>Rare</b> (less than 0.1%): Non-injection site varicella-type rash, non-injection site zoster-like rash</p>
<p><b>Postmarketing reports</b>: Rash<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Pain in extremity</p>
<p><b>Very rare</b> (less than 0.01%): Polymyalgia rheumatica</p>
<p><b>Postmarketing reports</b>: Arthralgia, myalgia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very rare</b> (less than 0.01%): Anaphylactic reaction</p>
<p><b>Postmarketing reports</b>: Hypersensitivity reactions including anaphylactic reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very rare</b> (less than 0.01%): Varicella</p>
<p><b>Postmarketing reports</b>: Herpes zoster (vaccine strain)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Lymphadenopathy<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Necrotizing retinitis (patients on immunosuppressive therapy)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Zostavax (zoster vaccine live)." Merck &amp; Company Inc, West Point, PA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about zoster vaccine live</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>11 Reviews</li>
<li>Drug class: viral vaccines</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zoster vaccine, live Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Zostavax</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Herpes Zoster, Prophylaxis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to zoster vaccine live: subcutaneous powder for injection</i></p><h3>General</h3><p>The most common adverse events were headache and injection site reactions.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site pain (up to 53.9%), injection site erythema (48.1%), injection site swelling (40.4%), pruritus (11.3%)</p><p><b>Common</b> (1% to 10%): Warmth, hematoma, induration</p><p><b>Postmarketing reports</b>: Injection site rash, injection site urticaria, transient injection site lymphadenopathy<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, asthenia<sup>[Ref]</sup></p><h3>Other</h3><p>The most common reported cause of death was cardiovascular disease (10 in the vaccine group, 8 in the placebo group).  The overall incidence of death occurring at any time during the study was similar between groups: 793 deaths (4.1%) in the vaccine group and 795 deaths (4.1%) in the placebo group.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Death, fever, asthenia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Congestive heart failure or pulmonary edema<sup>[Ref]</sup></p><p>Congestive heart failure or pulmonary edema occurred in 1.5% of patients receiving the vaccine versus 1.2% of patients receiving placebo in the AE monitoring substudy.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Respiratory infection, flu syndrome, rhinitis, respiratory disorder</p><p><b>Very rare</b> (less than 0.01%): Asthma exacerbation<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea</p><p><b>Postmarketing reports</b>: Nausea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Skin disorder</p><p><b>Rare</b> (less than 0.1%): Non-injection site varicella-type rash, non-injection site zoster-like rash</p><p><b>Postmarketing reports</b>: Rash<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Pain in extremity</p><p><b>Very rare</b> (less than 0.01%): Polymyalgia rheumatica</p><p><b>Postmarketing reports</b>: Arthralgia, myalgia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very rare</b> (less than 0.01%): Anaphylactic reaction</p><p><b>Postmarketing reports</b>: Hypersensitivity reactions including anaphylactic reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very rare</b> (less than 0.01%): Varicella</p><p><b>Postmarketing reports</b>: Herpes zoster (vaccine strain)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Lymphadenopathy<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Necrotizing retinitis (patients on immunosuppressive therapy)<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Zostavax (zoster vaccine live)." Merck &amp; Company Inc, West Point, PA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about zoster vaccine live</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>11 Reviews</li>
<li>Drug class: viral vaccines</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zoster vaccine, live Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Herpes Zoster, Prophylaxis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>